1型糖尿病
医学
临床试验
小岛
免疫学
质粒
糖尿病
免疫系统
疾病
dna疫苗
免疫耐受
干扰素
抗原
2型糖尿病
病毒学
临床研究阶段
Ⅰ型干扰素
自身免疫性疾病
胰岛素
内科学
重组DNA
作者
Carla J. Greenbaum,S. Alice Long,Stephen Eric Gitelman,JASON L. GAGLIA,Mark Daniels,Todd M. Brusko,Sandra M. Lord,Brian N. Bundy,Jeffrey P. Krischer,Michael J. Haller,Andrea K. Steck,Linda Anne DiMeglio,Carmella Evans‐Molina,Antoinette Moran,Priya Prahalad,Darrell M. Wilson,William E. Russell,Jennifer L. Sherr,Philip Raskin,Mark Allen Clements
出处
期刊:Diabetes
[American Diabetes Association]
日期:2026-01-21
卷期号:75 (3): 506-518
被引量:3
摘要
There is significant interest in antigen-specific approaches to delaying type 1 diabetes in preclinical stages and supporting tolerance after diagnosis. We conducted a phase I trial of a nonintegrating DNA plasmid constructed to secrete the type 1 diabetes antigen preproinsulin (PPI) and the immune modulatory cytokines transforming growth factor-β1 (TGF-β1), interleukin-10 (IL-10), and IL-2. In this placebo-controlled, double-masked study of 47 adults with stage 3 type 1 diabetes, we showed that the drug is safe and well tolerated, with most reported adverse events (AEs) categorized as grade 1 and with no clinically significant difference in AEs among treatment groups. There were no untoward metabolic or immune effects. We found pharmacodynamic evidence of treatment, as demonstrated by a dose-dependent type 1 interferon (IFN) signature. Plasmid DNA, representing a pharmocokinetic measure, was detected in the two highest dosing groups. We did not find global or antigen-specific immune cell changes following treatment with a DNA plasmid expressing PPI, IL-2, IL-10, and TGF-β1, and we did not detect immune changes driven by IL-2, IL-10, or TGF-β1. Our results support further trials of this novel tolerizing antigen construct. ARTICLE HIGHLIGHTS: Antigen-specific therapy is needed to induce tolerance in type 1 diabetes at early disease stages or in combination with immunotherapy. We conducted a phase I trial in type 1 diabetes of a novel plasmid construct expressing the islet antigen preproinsulin (PPI) and immunomodulatory cytokines transforming growth factor-β1 (TGF-β1), interleukin-10 (IL-10), and IL-2. The therapy was safe and well tolerated. Dose-dependent changes in DNA plasmid levels and type 1 interferon signatures were detected; however, global and antigen-specific immune changes to PPI, IL-2, IL-10, or TGF-β1 were not observed. Further trials are needed to assess efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI